Merck Gains Attention with Oral Cholesterol-Management Therapy Clearance

Merck (NYSE:MRK) recently gained attention after receiving regulatory clearance for an oral cholesterol-management therapy. This development expands Merck's cardiometabolic portfolio beyond its established oncology and vaccine franchises.

The company's oncology franchise, anchored by a widely used immunotherapy treatment, remains the largest contributor to the broader enterprise. Executives have described this franchise as the primary growth driver for the company.

Merck is diversifying beyond reliance on a single immunotherapy treatment ahead of patent expiration later in the decade. The drugmaker's vaccine franchise, spanning human papillomavirus prevention and pediatric immunization categories, represents a meaningful and recurring contributor to overall revenue.